Both Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals have obtained FDA approval for their generic versions of Fosamax, Merck & Co.'s osteoporosis drug. Barr got regulatory clearance to produce a 70-mg dose of the drug, while Teva's application was for 5-mg, 10-mg, 35-mg, 40-mg and 70-mg versions of the treatment.

Related Summaries